Management of Vernal Keratoconjunctivitis
Open Access
- 7 September 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Ophthalmology and Therapy
- Vol. 2 (2), 73-88
- https://doi.org/10.1007/s40123-013-0019-y
Abstract
Vernal keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. Affecting mainly children and young adults, it is an IgE- and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte and structural cell activation are involved. Treatment of VKC requires a multiple approach that includes conservative measures and pharmacologic treatment. Patients and parents should be made aware of the long duration of disease, its chronic evolution and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement. Mast cell stabilizers and antihistamines have been proven to be effective for the treatment of mild to moderate forms of VKC. In the most severe cases, topical steroids can be used as rescue medication to reduce conjunctival and corneal inflammation. Immunomodulators that have been investigated for VKC treatment include topical ocular preparations of cyclosporine A and tacrolimus. Topical cyclosporine A has been proven to be effective in the long-term treatment of VKC, significantly improving signs and symptoms without significant side effects.Keywords
This publication has 74 references indexed in Scilit:
- Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surfaceAllergy, 2012
- Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitisClinical Ophthalmology, 2012
- Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year studyJournal of Allergy and Clinical Immunology, 2011
- A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic ConjunctivitisJournal of Ocular Pharmacology and Therapeutics, 2010
- Use of Systemic T-lymphocyte Signal Transduction Inhibitors in the Treatment of Atopic KeratoconjunctivitisCornea, 2008
- Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitisBritish Journal of Ophthalmology, 2007
- Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patientsBritish Journal of Ophthalmology, 2007
- Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective studyActa Ophthalmologica Scandinavica, 2006
- Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitisAnnals of Allergy, Asthma & Immunology, 2002
- Therapeutic Options in Ocular Allergic DiseaseDrugs, 1995